Omnicell Stock News

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margin significantly.

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.

Omnicell (NASDAQ:OMCL) had its target price hoisted by equities researchers at BTIG Research from $210.00 to $220.00 in a research note issued on Wednesday, The Fly reports. The brokerage currently has a buy rating on the stock. BTIG Researchs target price would indicate a potential upside of 24.29% from the companys current price. Several other []

Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.

Brokerages predict that Omnicell, Inc. (NASDAQ:OMCL) will post earnings of $0.95 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Omnicells earnings. Omnicell posted earnings per share of $0.91 during the same quarter last year, which would indicate a positive year-over-year growth rate of 4.4%. The business []

Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.

Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.

Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.

Investors are optimistic about Integra (IART) given its better-than-expected results and robust performance of the CSS arm in the third quarter.